A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)
A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multicenter Dose Ranging Study With the Beta-3 Agonist YM178 in Patients With Symptomatic Overactive Bladder
1 other identifier
interventional
1,108
15 countries
84
Brief Summary
The study will examine which dose of YM178 is best in terms of efficacy, safety and tolerability compared to placebo and compared to tolterodine, a marketed product.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_2
84 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 14, 2006
CompletedFirst Posted
Study publicly available on registry
June 15, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2007
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2007
CompletedJuly 2, 2013
July 1, 2013
June 14, 2006
July 1, 2013
Conditions
Keywords
Interventions
Eligibility Criteria
You may qualify if:
- Patients over 18 years suffering from overactive bladder (OAB) for more than 3 months
You may not qualify if:
- Pregnant and breastfeeding women
- Any medical condition or need for co-medication which interferes with the drug under investigation (YM178) or the comparator (tolterodine)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Astellas Pharma Inclead
- Astellas Pharma Europe B.V.collaborator
Study Sites (84)
3 Sites
Antwerp, Belgium
2 Sites
Brussels, Belgium
Unknown Facility
Ghent, Belgium
Unknown Facility
Leuven, Belgium
Unknown Facility
Liège, Belgium
Unknown Facility
Brno, Czechia
Unknown Facility
MÄ›lnÃk, Czechia
Unknown Facility
Ostrava, Czechia
3 Sites
Prague, Czechia
Unknown Facility
Ústà nad Labem, Czechia
Unknown Facility
ZlÃn, Czechia
Unknown Facility
Holbæk, Denmark
Unknown Facility
Kolding, Denmark
Unknown Facility
Roskilde, Denmark
2 Sites
Nantes, France
2 Sites
Paris, France
Unknown Facility
Bad Ems, Germany
Unknown Facility
Bamberg, Germany
Unknown Facility
Bautzen, Germany
Unknown Facility
Berlin, Germany
Unknown Facility
Dresden, Germany
Unknown Facility
Frankfurt, Germany
Unknown Facility
Hagenow, Germany
Unknown Facility
Halle, Germany
Unknown Facility
Hamburg, Germany
Unknown Facility
Koblenz, Germany
Unknown Facility
Leipzig, Germany
Unknown Facility
München, Germany
Unknown Facility
Radebeul, Germany
Unknown Facility
Trier, Germany
Unknown Facility
Uetersen, Germany
3 Sites
Athens, Greece
Unknown Facility
Pátrai, Greece
Unknown Facility
Miskolc, Hungary
Unknown Facility
NyÃregyháza, Hungary
Unknown Facility
Pécs, Hungary
Unknown Facility
Sopron, Hungary
Unknown Facility
Szeged, Hungary
Unknown Facility
Tatabánya, Hungary
Unknown Facility
Catanzaro, Italy
Unknown Facility
Milan, Italy
Unknown Facility
Modena, Italy
Unknown Facility
Padua, Italy
Unknown Facility
Roma, Italy
Unknown Facility
Sassari, Italy
Unknown Facility
Torino, Italy
Unknown Facility
Udine, Italy
Unknown Facility
Varese, Italy
Unknown Facility
Amsterdam, Netherlands
Unknown Facility
Apeldoorn, Netherlands
Unknown Facility
Arnhem, Netherlands
Unknown Facility
Eindhoven, Netherlands
Unknown Facility
Enschede, Netherlands
Unknown Facility
Maastricht, Netherlands
Unknown Facility
Bergen, Norway
Unknown Facility
Oslo, Norway
Unknown Facility
Tønsberg, Norway
Unknown Facility
Bialystok, Poland
Unknown Facility
Katowice, Poland
Unknown Facility
Kielce, Poland
Unknown Facility
Lublin, Poland
3 Sites
Warsaw, Poland
3 Sites
Wroclaw, Poland
7 Sites
Moscow, Russia
3 Sites
Saint Petersburg, Russia
2 Sites
Barcelona, Spain
Unknown Facility
Bilbao, Spain
2 Sites
Madrid, Spain
Unknown Facility
Manacor, Spain
Unknown Facility
Miranda de Ebro, Spain
Unknown Facility
San Juan de Alica, Spain
Unknown Facility
Seville, Spain
Unknown Facility
Vigo, Spain
Unknown Facility
Gothenburg, Sweden
2 Sites
Stockholm, Sweden
Unknown Facility
Birmingham, United Kingdom
Unknown Facility
Blackburn, United Kingdom
Unknown Facility
Chichester, United Kingdom
Unknown Facility
Croydon, United Kingdom
Unknown Facility
London, United Kingdom
Unknown Facility
Reading, United Kingdom
Unknown Facility
Sheffield, United Kingdom
Unknown Facility
Southampton, United Kingdom
Unknown Facility
Swansea, United Kingdom
Related Publications (1)
Stoniute A, Madhuvrata P, Still M, Barron-Millar E, Nabi G, Omar MI. Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2023 May 9;5(5):CD003781. doi: 10.1002/14651858.CD003781.pub3.
PMID: 37160401DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Astellas Pharma
Astellas Pharma Europe B.V.
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
June 14, 2006
First Posted
June 15, 2006
Primary Completion
March 1, 2007
Study Completion
March 1, 2007
Last Updated
July 2, 2013
Record last verified: 2013-07